Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile

Journal of Psychopharmacology

Volumn 18, Issue 3, 2004, Pages 375-383

  Hirose, Tsuyoshi ^a   Uwahodo, Yasufumi ^a   Yamada, Sakiko ^a   Miwa, Takashi ^a   Kikuchi, Tetsuro ^a   Kitagawa, Hisashi ^a   Burris, Kevin D ^b   Altar, C Anthony ^c   Nabeshima, Toshitaka ^d  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b Palatin Technologies   (United States)

^c Psychiatric Genomics Inc   (United States)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aripiprazole; Efficacy; Olanzapine; Risperidone; Side effects

Indexed keywords

5 HYDROXYTRYPTOPHAN; 5 METHOXY N,N DIMETHYLTRYPTAMINE; APOMORPHINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; DOPA; DOPAMINE RECEPTOR; HALOPERIDOL; NORADRENALIN; OLANZAPINE; PHYSOSTIGMINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; FOREBRAIN; HEAD TWITCH; LETHALITY; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PTOSIS; RAT; STEREOTYPY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLEPHAROPTOSIS; CATALEPSY; DIHYDROXYPHENYLALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD MOVEMENTS; MALE; METHOXYDIMETHYLTRYPTAMINES; MICE; MICE, INBRED ICR; PIPERAZINES; PROSENCEPHALON; QUINOLONES; RATS; RATS, WISTAR; RISPERIDONE; SEROTONIN; STEREOTYPED BEHAVIOR;

EID: 6044224986     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110401800308     Document Type: Article

References (55)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin R M, Seibyl J P, Bowers M, van Dyck C H, Charney D S, Innis R B, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761-767
2. 2 receptors: An autoradiographic analysis in rat brain. Brain Res Bull 16: 517-525
3. Andersen H L, Kilpatrick I C (1996) Prevention by (+/-)-8-hydroxy-2-(di- n-propylamino) tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. Br J Pharmacol 118 (2): 421-427
4. 2 receptors in the rat medial prefrontal cortex. J Pharmacol Exp Ther 252: 171-178
5. Bhana N, Foster R H, Olney R, Plosker G L (2001) Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61: 111-161
6. Borison R L (1997) Recent advances in the pharmacotherapy of schizophrenia. Harv Rev Psychiatry 4: 255-271
7. Bourin M, Poncelet M, Chermat R, Simon P (1983) The value of the reserpine test in psychopharmacology. Arzneimittelforschung 33: 1173-1176
8. Buckley PF (2001) Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 50: 912-924
9. 2 dopamine receptors. Int J Neuropsychopharmacol 3 (Suppl 1): S129
10. 2 receptors. J Pharmacol Exp Ther 302: 381-389
11. Conley R R (2000) Risperidone side effects. J Clin Psychiatry 61 (Suppl 8): 20-25
12. Costall B, Naylor RJ (1973) On the mode of action of apomorphine. Eur J Pharamcol 21: 350
13. Deniard M J, Meignen J, DeFeudis F V (1983) Reversal of reserpine-induced ptosis in the mouse by alpha-adrenoceptor-agonists. Psychopharmacology (Berl) 80: 243-248
14. Dray A, Davies J, Oakley N R, Tongroach P, Vellucci S (1978) The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res 151: 431-442
15. 108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci 98: 6917-6922
16. 1A receptors: pharmacological, biochemical, functional, and regulatory properties. Ann NY Acad Sci 600: 114-129
17. Henderson D C (2002) Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16: 77-89
18. Hjorth S, Carlsson A, Wikstrom H, Lindberg P, Sanchez D, Hacksell U, Arvidsson L E, Svensson U, Nilsson J L (1981) 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci 28: 1225-1238
19. Hoffman D C, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 120: 128-133
20. Horacek J (2000) Novel antipsychotics and extrapyramidal side effects. Theory and reality. Pharmacopsychiatry 33 (Suppl 1): 34-42
21. Howanitz E, Pardo M, Smelson D A, Engelhart C, Eisenstein N, Stern R G, Losonczy M F (1999) The efficacy and safety of clozapine vs. chlorpromazine in geriatric schizophrenia. J Clin Psychiatry 60: 41-44
22. 1A receptor. Eur J Pharmacol 441: 137-140
23. Kane J M, Carson W H, Saha A R, McQuade R D, Ingenito G C, Zimbroff D L, Ali M W (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763-771
24. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466-476
25. Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Ann Rev Med 52: 503-517
26. Kelland M D, Freeman A S, Chiodo L A (1990) Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 253: 803-811
27. Kenakin T P, Beek D (1984) Relative efficacy of prenalterol and pirbuterol for beta-1 adrenoceptors: measurement of agonist affinity by alteration of receptor number. J Pharmacol Exp Ther 229: 340-345
28. Kennedy J S, Bymaster F P, Schuh L, Calligaro D O, Nomikos G, Felder C C, Bernauer M, Kinon B J, Baker R W, Hay D, Roth H J, Dossenbach M, Kaiser C, Beasley C M, Holcombe J H, Effron M B, Breier A (2001) A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry Suppl 1: S33-S61
29. 2 receptor antagonistic activity. J Pharmacol Exp Ther 274: 329-336
30. Lawler C P, Prioleau C, Lewis M M, Mak C, Jiang D, Schetz J A, Gonzalez A M, Sibley D R, Mailman R B (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20: 612-627
31. Lieberman J, Carson W H, Saha A R, Stringfellow J C, Archibald D G, Kujawa M J, Iwamoto T (2002) Meta-analysis of the efficacy of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 5 (Suppl 1): S186
32. Loew E R, Micetich A (1984) Adrenergic blocking drugs I. Comparisons of effectiveness in decreasing epinephrine toxicity in mice. J Pharmacol Exp Ther 93: 434-443
33. Lund B C, Perry P J (2000) Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opin Pharmacother 1: 305-323
34. McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T (2002) Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharm 2002; 5 (Suppl 1): S176
35. Marder S R, McQuade R D, Stock E, Kaplita S, Marcus R, Safferman A Z, Saha A R, Ali M W, Iwamoto T (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res 61: 123-136
36. Martin A, Altar C A, Thurkauf A (2002) Antipsychotics. In Abraham D J (ed.), Burger's medicinal chemistry and drug discovery, 6th edn. Wiley, Mississauga, ON, Canada
37. Meller E, Helmer-Matyjek E, Bohmaker K, Adler C H, Friedhoff A J, Goldstein M (1986) Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur J Pharmacol 125: 311-314
38. Meller E, Bohmaker K, Namba Y, Friedhoff A J, Goldstein M (1987) Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 31: 592-598
39. Meltzer H Y, Nash J F (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43: 587-605
40. Millan M J, Schreiber R, Dekeyne A, Rivet J M, Bervoets K, Mavridis M, Sebban C, Maurel-Remy S, Newman-Tancredi A, Spedding M, Muller O, Lavielle G, Brocco M (1998) S 16924((R)-2-[1-[2-(2,3-dihydrobenzo[1,4]dioxin-5-yloxy)-ethyl] -pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286: 1356-1373
41. Milson J A, Pycock C J (1976) Effects of drugs acting on cerebral 5-hydroxytryptamine mechanisms on dopamine-dependent turning behaviour in mice. Br J Pharmacol 56: 77-85
42. Minneman K P, Abel P W (1984) Relationship between alpha 1-adrenoceptor density and functional response of rat vas deferens. Studies with phenoxybenzamine. Naunyn Schmiedebergs Arch Pharmacol 327: 238-246
43. Petrie J L, Saha A R, McEvoy J P (1997) Aripiprazole, a new novel atypical antipsychotic: Phase II clinical trial result. Eur Neuropsychopharmacol 7 (Suppl 2): S227
44. Potkin S G, Saha A R, Kujawa M J, Carson W H, Ali M W, Stock E, Stringfellow J, Ingenito G G, Marder S R (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60: 681-690
45. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144: 20-29
46. Puech A J, Rioux P, Poncelet M, Brochet D, Chermat R, Simon P (1981) Pharmacological properties of new antipsychotic agents: Use of animal models. Neuropharmacology 20: 1279-1284
47. Qi J H, Li B H (1992) Effects of alpha adrenoceptor agonists and antagonists on palpebral fissure and lacrimation in mice. Zhongguo Yao Li Xue Bao 13: 153-156
48. Russell J M, Mackell J A (2001) Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15: 537-551
49. 2 receptors. Life Sci 60: 207-216
50. 2 receptors. Proc Natl Acad Sci USA 97: 7673-7675
51. 1A receptor activation. Neuropsychopharmacology 21: 622-631
52. Stone E A, Zhang Y, Rosengarten H, Yeretsian J, Quartermain D (1999) Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice. Neuroscience 94: 1245-1252
53. 2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharmacol Biochem Behav 47: 509-513
54. Weinberger D R, Aloia M S, Goldberg T E, Berman K F (1994) The frontal lobes and schizophrenia. J Neuropsychiatry Clin Neurosci 6: 419-427
55. 2 receptor antagonist. Life Sci 42: 1941-54